DIL Dyadic International

Dyadic International, Inc. (AMEX:DIL), a biotechnology company engaged in the development, manufacture and sale of biological products, today announced changes to its Scientific Advisory Board (SAB). Joining Dyadic's SAB are Arnold Demain, Ph.D., Professor of Industrial Microbiology, Emeritus, Massachusetts Institute of Technology, Carlos Barbas, III, Ph.D., Kellogg Professor and Chair of Molecular Biology and Chemistry at The Scripps Research Institute (TSRI), and Joseph Villafranca, Ph.D., Executive Vice President, Pharmaceutical Development and Operations, Neose Technologies, Inc. Leaving Dyadic's SAB are Edward McGuire, Ph.D., former Vice President of Research & Development, Neose Technologies, Inc., and Michael Koslowski, Ph.D., Chief Scientist, Kreido Laboratories. "The new SAB members fit exceptionally well into Dyadic's strategy for the future and will help guide the company to select the best opportunities among the numerous fields where Dyadic's technologies can be applied," commented Mark Emalfarb, Dyadic's President and CEO. "We are pleased to welcome these eminent scientists and look forward to their contributions to the advancement of Dyadic's C1 Host Technology and commercialization efforts of new and existing products and processes." Drs. Demain, Barbas, and Villafranca join other scientific leaders on Dyadic's SAB, which include chairman Dr. Richard Lerner, Dr. Gerry Fink, and Drs. Arkady Sinitsyn, Peter Punt and Cees van den Hondel. "Departing SAB members, Drs. McGuire and Koslowski played an important role in advancing Dyadic's science and technology. Their scientific guidance and dedicated service over the years are greatly appreciated and we wish them well in their future endeavors," added Mark Emalfarb. Bios for Drs. Demain, Barbas and Villafranca follow below. For complete bios of all of Dyadic's SAB's current members, please visit Dyadic's website at http://www.dyadic-group.com. Arnold Demain, Ph.D. Dr. Demain has been in the forefront of industrial microbiology and biotechnology for over four decades and has been involved in the research and commercialization of a number of fermentation based pharmaceutical processes. He is currently a Fellow at Drew University's Charles A. Dana Institute for Scientists Emeriti. Previously, Dr. Demain was at the Massachusetts Institute of Technology (MIT) for 32 years, where he most recently served as Professor of Industrial Microbiology in the Department of Biology. Before going to MIT, Dr. Demain spent fifteen years at Merck & Co., where he held various positions in R&D and management focused on fermentation microbiology. His leadership in the area of fermentation is evidenced by over 470 publications, 10 books of which he is coeditor or coauthor, 20 U.S. patents and his election to the presidency of the Society for Industrial Microbiology in 1990, membership in the National Academy of Sciences in 1994, the Mexican Academy of Sciences in 1997 and the Hungarian Academy of Sciences in 2001. Dr. Demain received his Ph.D. in Microbiology from University of California. Carlos Barbas, Ph.D. Dr. Barbas is a Professor of The Scripps Research Institute, Departments of Molecular Biology and Chemistry and The Skaggs Institute for Chemical Biology. He holds the Janet and W. Keith Kellogg II endowed Chair in Molecular Biology and Chemistry. Dr. Barbas has received honours including the Investigator Award from the Cancer Research Institute, The Scholar Award of the American Foundation for AIDS Research, and the Presidential Green Chemistry Challenge Award. He is the author of over 200 scientific articles and is a named inventor on 32 issued U.S. patents. Key accomplishments in the area of biotechnology pioneered by Dr. Barbas and his colleagues include the development of the first human antibody phage libraries, development of the first synthetic antibodies, the development of the first artificial transcription factors capable of regulating endogenous genes, and chemically programmed antibodies-the CovX core technology. Dr. Barbas received his Ph.D. in Organic Chemistry from Texas A&M University. Joseph Villafranca, Ph.D. Dr. Villafranca has served as Executive Vice President, Pharmaceutical Development and Operations at Neose Technologies, Inc., since February 2004. He joined Neose in October 2002 as Senior Vice President, Pharmaceutical Development and Operations. From 1992 to 2002 he held various positions at Bristol-Myers Squibb, serving most recently as Vice President of Biologics Strategy and Biopharmaceuticals Operations. Prior to Bristol-Myers, Dr. Villafranca spent 20 years at Penn State University, including eight years as the Evan Pugh Professor of Chemistry. Dr. Villafranca earned a B.S. in Chemistry from the State University of New York and a Ph.D. in Biochemistry/Chemistry from Purdue University. He completed his post-doctoral training in Biophysics at the Institute for Cancer Research in Philadelphia. About Dyadic Dyadic International, Inc., is engaged in the development, manufacture and sale of biological products (proteins, enzymes, peptides and other bio-molecules), as well as the licensing of its enabling proprietary technology to business collaborators for the discovery, development and manufacture of biological products from genes. Dyadic markets its products and services for applications in the textile, chemical, agricultural, pulp & paper, pharmaceutical, biotechnology and other industries, using its proprietary C1 Host Technology and C1 Expression and Screening Systems for the discovery, development and production of biological products. Cautionary Statement for Forward-Looking Statements Certain statements contained in this press release are "forward-looking statements." These forward-looking statements involve risks and uncertainties that could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For a discussion of these risks and uncertainties, please see our filings from time to time with the Securities and Exchange Commission, which are available free of charge on the SEC's web site at http://www.sec.gov, including our Annual Report on Form 10-KSB for the year ended December 31, 2004, and our Quarterly Report for the quarter ended June 30, 2005 on Form 10-QSB. Except as required by law, we expressly disclaim any intent or obligation to update any forward-looking statements.